Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase
Ari Zimran(Hebrew University of Jerusalem), Gregory A. Grabowski(Cincinnati Children's Hospital Medical Center), Derralynn Hughes(Royal Free London NHS Foundation Trust), Gregory M. Pastores(New York University), Laurie D. Smith(Children's Mercy Hospital), Anna Tylki‐Szymańska(Children's Memorial Health Institute), Rebecca Mardach(Kaiser Permanente), Margaret A. Heisel‐Kurth(Children's Minnesota), Pilar Giraldo(Université Paris-Saclay), David M. Zahrieh(Takeda (United States)), Deborah Elstein(Shaare Zedek Medical Center), Nicola Longo(Center for Human Genetics), Christine M. Eng(Baylor College of Medicine), Paul M. Fernhoff, Eric Crombez(University of California, Los Angeles), Juan Ruiz(Takeda (United States)), Paul Harmatz(Unknown), Joel Charrow(Northwestern University), William J. Rhead(Children's Hospital of Wisconsin)
Cited by 62
Related Papers
Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders
|New England Journal of Medicine|2013|2k
Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis
|New England Journal of Medicine|2012|1.4k
Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation
|New England Journal of Medicine|2016|774
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555